US Bivalent COVID Booster Purchases Would Cover About Half Of Population At More than 50% Price Hike
Executive Summary
The government is paying a premium for updated vaccines despite the much smaller data packages that will be available at the time of a potential authorization and rollout. The administration also currently lacks funding for boosters for all, but demand may not necessitate such a supply.
You may also be interested in...
Overhyped? White House COVID Coordinator's Claims About New Boosters Go Beyond Data
Ashish Jha made promises about the upcoming bivalent COVID-19 boosters that neither he nor the companies are likely going to be able to keep when the rollout begins.
EU Boosts COVID-19 Vaccine Supplies With Moderna & HIPRA Deals
New supply arrangements with the two firms are expected to offer greater protection to people in Europe as the autumn/winter season approaches. The EU’s health crisis preparedness body HERA has also identified its “top three health threats.”
Lilly Needs Updated FDA Authorization To Sell COVID Antibody On Commercial Market
Biden administration will run out of supply of Lilly’s covid antibody bebtelovimab in August, forcing a shift to commercial market due to lack of funds. The transition will require changes to the emergency use authorization and involve a price hike.